Comparison of non-severe COVID-19 pneumonia patients treated with lopinavir/ritonavir and favipiravir

• Main Authors: Bengü Şaylan, Omer Ayten
• Format: Article
• Language: English
• Published: Journal of Surgery and Medicine 2020-11-01
• Series: Journal of Surgery and Medicine
• Subjects: covid-19; ağır olmayan pnomoni; favipiravir; lopinavir/ritonavir; covid 19; non severe pneumonia; lopinavir ritonavir
• Online Access: https://dergipark.org.tr/en/pub/josam/issue/57748/795283

Aim: There is no proven medical treatment for COVID-19 to date. We aimed to evaluate the effectiveness of LPV/r and FVR treatments in non-severe COVID-19 pneumonia patients and compare the clinical outcomes. Methods: In this retrospective cohort study, the data of non-severe COVID-19 pneumonia patients treated with lopinavir/ritonavir and FVR were analyzed. Results: A total of 91 non-severe COVID-19 patients, 33 (36.2%) treated with LPV/r and 58 (63.8%) treated with FVR, were included in the study. The mean ages of the LPV/r group and FVR group were 53.1 (13) years and 57.2 (17.44) years, respectively (P=0.24). There was no statistically significant difference between the two groups in terms of comorbidities (P=0.06). FVR patients had higher radiological weight scores than LPV/r patients, but this was not statistically significant (8.67 (3.7) vs 7.66 (3.22) P=0.2, respectively). While SpO2 levels of FVR patients at the time of admission were lower than those of LPV/r patients, CRP levels were higher (92.22 (2.8) vs 97.87 (2.05), P